ADAM2

Across TCGA pan-cancer cohorts, ADAM2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ADAM2 data layer compared with 16 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ADAM2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ADAM2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

LSCC, PDAC, and LUAD are the cancer types where ADAM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	All	0.981	0.763	.002	30	view →
PDAC	DFS	Median	All	0.315	0.486	.007	7	view →
LUAD	OS	Tertile	III,IV	0.222	0.885	.021	4	view →
GBM	DFS	Quartile	All	0.512	0.217	.033	2	view →
CCRCC	OS	Quartile	All	0.727	0.953	.037	2	view →
HNSC	DFS	Median	III,IV	1.000	0.939	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ADAM2–LSCC (OS)

Open the LSCC breakdown →